ArticleFolia microbiologica2021
Anti-phage serum antibody responses and the outcome of phage therapy.
Article in Folia microbiologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
- Targeting STEC-induced edema disease in weaned piglets: prophylactic oral phage P-GXEC-L2P5 attenuates bacterial colonization, toxin production, and endothelial damage.Veterinary research · 2025Article
- Review
- Large-Scale Genomic Analysis of CpG-Mediated Immunogenicity in Bacteriophages and a Novel Predictive Risk Index.bioRxiv : the preprint server for biology · 2025Article
- Translational research priorities for bacteriophage therapeutics.Essays in biochemistry · 2024Review
- Phage K exposure generates phage-neutralizing activity in a rabbit model-humoral receptiveness may impact efficacy of phage therapy.Antimicrobial agents and chemotherapy · 2024Article
- Bacteriophages: a double-edged sword in the gastrointestinal tract.Frontiers in microbiomes · 2024Review
- Bacteriophages as Potential Clinical Immune Modulators.Microorganisms · 2023Review
- Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.Pharmaceutical research · 2023Review
- Repetitive Exposure to Bacteriophage Cocktails againstViruses · 2023Article
- Characteristics of EnvironmentalPharmaceutics · 2023Article
- A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.Viruses · 2022Article
- Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?Pharmaceuticals (Basel, Switzerland) · 2021Article
- Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Article
- The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis.Antibiotics (Basel, Switzerland) · 2021Review
- [Bacteriophage Therapy: Retrospective Review and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
We examined the appearance of serum anti-phage antibodies in 25 patients with chronic sinusitis treated with phage therapy (PT). Approximately 30% of patients with weak antibody responses responded positively to PT, which was similar to the results of treatment achieved in a group of patients with high antibody production. In addition, there was no correlation between antibody level and the outcome of PT. These data, derived from a homogenous group of patients, confirm our earlier findings suggesting that the prognostic significance of serum anti-phage antibodies for the outcome of PT should be determined by relevant clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.